Sanofi’s healthy Q1 performance hailed by markets
25/04/24 -"Q1 results surpassed expectations, on the back of a strong showing from immunology drug Dupixent, RSV vaccine Beyfortus and the new launches of recent years. Moreover, the management re-affirmed its ..."
Pages
70
Language
English
Published on
25/04/24
You may also be interested by these reports :
03/05/24
Genmab’s Q1 sales exceeded expectations, although profitability fell somewhat short. This robust performance was led by strong growth across all the ...
03/05/24
We have rolled forward our model to include a new forecast year (2026) which will also see continued healthy top-line growth and profitability ...
02/05/24
CureVac did not really tidy things up. The cost-cutting measures, as presented, are insufficient and do not meet our ideal scenario of a focused and ...
02/05/24
The Q1 results exceeded the street’s expectations, driven by the strong momentum for Novo’s diabetes and obesity offerings. While the management ...